Leland Gershell analyst OPPENHEIMER

Currently out of the existing stock ratings of Leland Gershell, 148 are a BUY (93.08%), 5 are a SELL (3.14%), 6 are a HOLD (3.77%).

Leland Gershell

Work Performance Price Targets & Ratings Chart

Analyst Leland Gershell, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 33.39% that have a potential upside of 31.62% achieved within 143 days.

Leland Gershell’s has documented 354 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SLNO, Soleno Therapeutics at 28-Oct-2024.

Wall Street Analyst Leland Gershell

Analyst best performing recommendations are on BXRX (BAUDAX BIO ).
The best stock recommendation documented was for SLNO (SOLENO THERAPEUTICS) at 9/15/2023. The price target of $14 was fulfilled within 11 days with a profit of $9.1 (185.71%) receiving and performance score of 168.83.

Average potential price target upside

ACST Acasti Pharma ADMA ADMA Biologics AGRX Agile Thrpe ALNY Alnylam Pharmaceuticals AMRN Amarin PLC ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical BXRX Baudax Bio  CASI CASI Pharmaceuticals CERC Cerecor CPRX Catalyst Pharmaceuticals EVFM Evofem Biosciences MGEN Viridian Therapeutics MIST Milestone Pharmaceuticals REPH Recro Pharma TARA Protara Therapeutics URGN UroGen Pharma Ltd VERU Veru BBI Brickell Biotech PLXP PLx Pharma CRXT Clarus Therapeutics Holdings HZNP Horizon Pharma PLC LUMO Lumos Pharma AVTX Avalo Therapeutics CLNN Clene . TRVI Trevi Therapeutics XLRN Acceleron Pharma CRBP Corbus Pharmaceuticals EPZM Epizyme OTLK OUTLOOK THERAPEUTICS INC SLNO Soleno Therapeutics XFOR X4 Pharmaceuticals NCNA NuCana PLC TEVA Teva Pharma Industries Ltd ADR VRDN Viridian Therapeutics CRNX Crinetics Pharmaceuticals PDSB PDS Biotechnology Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$2.5

$-0.28 (-10.07%)

1 years 8 months 24 days ago
(15-Feb-2023)

1/1 (100%)

$1.86 (290.63%)

145

Buy

$30

2 years 4 months 17 days ago
(22-Jun-2022)

0/1 (0%)

$22.32 (290.63%)

Buy

4 years 2 months 8 days ago
(31-Aug-2020)

0/1 (0%)

$59.52 (163.16%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Leland Gershell is most bullish on?

Potential upside of $64.72 has been obtained for ASND (ASCENDIS PHARMA AS)

Which stock is Leland Gershell is most reserved on?

Potential downside of $5.72 has been obtained for VRDN (VIRIDIAN THERAPEUTICS)

What Year was the first public recommendation made by Leland Gershell?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?